<SEC-DOCUMENT>0001437749-21-002572.txt : 20210211
<SEC-HEADER>0001437749-21-002572.hdr.sgml : 20210211
<ACCEPTANCE-DATETIME>20210211143550
ACCESSION NUMBER:		0001437749-21-002572
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210211
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210211
DATE AS OF CHANGE:		20210211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39563
		FILM NUMBER:		21618805

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			GA
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			GA
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>govx20210211_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head>
	<title>govx20210211_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 2/11/2021 3:46:56 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;<font style="font-family:Times New Roman;font-size:18pt;"><b>FORM 8-K</b></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CURRENT REPORT</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Pursuant to Section 13 or 15(d) of the</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Securities Exchange Act of 1934</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Date of report (Date of earliest event reported):&nbsp;&nbsp;</b><b>February 11, 2021</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;"><b>GEOVAX LABS, INC.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:31.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Delaware</b></p>
			</td>
			<td style="vertical-align:bottom;width:4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:29.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>001-39563</b></p>
			</td>
			<td style="vertical-align:bottom;width:1.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:32.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>87-0455038</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:31.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(State or other jurisdiction of</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>incorporation or organization)</b></p>
			</td>
			<td style="vertical-align:bottom;width:4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:29.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(Commission File No.)</b></p>
			</td>
			<td style="vertical-align:bottom;width:1.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:32.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(IRS Employee Identification No.)</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>1900 Lake Park Drive, Suite 380</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Smyrna, Georgia 30080</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(Address of principal executive offices) (Zip code)</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(678) 384-7220</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(Registrant&#8217;s telephone number, including area code)</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13(e)-4(c))</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:41%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Title of each class</p>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:18.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Trading</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Symbol(s)</p>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:40.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Name of each exchange on which registered</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:41%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Common Stock, par value $0.001 per share</p>
			</td>
			<td style="vertical-align:middle;width:18.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">GOVX</p>
			</td>
			<td style="vertical-align:middle;width:40.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">The Nasdaq Capital Market</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:41%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Warrants to Purchase Common Stock</p>
			</td>
			<td style="vertical-align:middle;width:18.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">GOVXW</p>
			</td>
			<td style="vertical-align:middle;width:40.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">The Nasdaq Capital Market</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Emerging growth company &#9744;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial reporting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act. &#9744;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#8220;Registrant&#8221; or the &#8220;Company&#8221;) from time to time with the Securities and Exchange Commission (collectively the &#8220;Filings&#8221;) contain forward looking statements and information that are based upon beliefs of, and information currently available to, the Registrant&#8217;s management as well as estimates and assumptions made by the Registrant&#8217;s management. When used in the Filings the words &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;future&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221; or the negative of these terms and similar expressions as they relate to the Registrant or the Registrant&#8217;s management identify forward looking statements.&nbsp;&nbsp;Such statements reflect the current view of the Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Registrant&#8217;s industry, operations and results of operations and any businesses that may be acquired by the Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Except as required by law, the Registrant does not undertake to update its forward-looking statements.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item 1.01</b></p>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Entry into a Material Definitive Agreement.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>&nbsp;</b></i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><i><b>Public Offering</b></i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">On February 11, 2021, the Company closed its previously announced underwritten bought deal offering (the &#8220;Offering&#8221;) in which, pursuant to the underwriting agreement (the &#8220;Underwriting Agreement&#8221;) entered into between the Company and Maxim Group LLC, as the underwriter (the &#8220;Underwriter&#8221;), dated February 8, 2021, the Company issued and sold an aggregate of 1,644,000 shares of its common stock (the &#8220;Shares&#8221;), which included 204,000 shares sold pursuant to the full exercise of the underwriter&#8217;s option to purchase additional shares, at a price to the public of $6.25 per Share, less underwriting discounts and commissions. The gross proceeds received by the Company at the closing of the Offering on February 11, 2021 pursuant to such sales were approximately $10.3 million, prior to deducting underwriting discounts and commissions and other estimated Offering expenses.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Additionally, as previously announced, the Company issued to the Underwriter, as a portion of the underwriting compensation payable to the Underwriter, warrants to purchase up to a total of 72,000 shares of Common Stock (the &#8220;Underwriter&#8217;s Warrant Agreement&#8221;). The shares subject to the Underwriter&#8217;s Warrant Agreement are exercisable at $6.875 per share, are initially exercisable 180 days after the effective date of the Offering and have a term of three years from their initial exercise date. Pursuant to the customary FINRA rules, the Underwriter&#8217;s Warrant Agreement are subject to a lock-up agreement pursuant to which the Underwriter will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will it engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from the effective date of the registration statement. A form of the Underwriter&#8217;s Warrant Agreement is incorporated herein by reference from the registrant&#8217;s Current Report on Form 8-K filed February 11, 2021.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Shares were issued pursuant to the Company&#8217;s registration statement on Form S-3 (File No. 333-252437), filed by the Company with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on July 20, 2020, as amended, which was declared effective on February 3, 2021. A final prospectus relating to the Offering was filed with the Commission on February 11, 2021.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item 8.01</b></p>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Other Events.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Company issued a press release on February 11, 2021 announcing the closing of the Offering. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item 9.01</b></p>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Financial Statements and Exhibits.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 12%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><u>Exhibit No.</u></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Description</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 12%;">&nbsp;</td>
			<td style="vertical-align: top; width: 88%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 12%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">99.1</p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_226046.htm" style="-sec-extract:exhibit;">Closing press release dated February 11, 2021</a></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SIGNATURE</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date: February 11, 2021</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:50%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">GEOVAX LABS, INC.</p>
			</td>
			<td style="vertical-align: top; width: 13%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 13%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 13%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 34%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Mark W. Reynolds</p>
			</td>
			<td style="vertical-align: top; width: 13%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 34%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Mark W. Reynolds</p>
			</td>
			<td style="vertical-align: top; width: 13%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 34%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Financial Officer</p>
			</td>
			<td style="vertical-align: top; width: 13%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_226046.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_226046.htm</title>

	<!-- Generated by ThunderDome Portal - 2/11/2021 3:33:11 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin-bottom: 0; text-align: right; margin-top: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin-bottom: 0; text-align: left; margin-top: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<div><img alt="logo01.jpg" src="logo01.jpg"></div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>GeoVax&nbsp;Announces Closing of $10.3&nbsp;Million Bought Deal Offering </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Atlanta, GA, February 11, 2021 &#8211;&nbsp;GeoVax Labs, Inc.&nbsp;</b>(NasdaqCM: GOVX) (&#8220;GeoVax&#8221; or the &#8220;Company&#8221;), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the closing of its bought deal offering of 1,644,000 shares of its common stock, which included 204,000 shares sold pursuant to the full exercise of the underwriter&#8217;s option to purchase additional shares, at a price to the public of $6.25, less underwriting discounts and commissions. The gross proceeds from the offering were approximately $10.3 million, before deducting underwriting discounts and commissions and estimated offering expenses.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Maxim Group LLC acted as the sole book-running manager for the offering.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The offering was conducted pursuant to the Company&#8217;s registration statement on Form S-3 (File No. 333-252437), as amended, previously filed with and subsequently declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;). A final prospectus relating to the offering was filed on February 11, 2021 with the SEC and is available on the SEC&#8217;s website at http://www.sec.gov. Electronic copies of the final prospectus relating to this offering may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, or by telephone at (212) 895-3745.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>About GeoVax</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">GeoVax&#8217;s current development programs are focused on preventive vaccines against COVID-19, HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against multiple cancers. The Company has designed a preventive HIV vaccine candidate to fight against the subtype of HIV prevalent in the commercial markets of the Americas, Western Europe, Japan, and Australia; human clinical trials for this program are managed by the HIV Vaccine Trials Network (HVTN) with the support of the National Institutes of Health (NIH). GeoVax&#8217;s HIV vaccine is also part of two separate collaborative efforts to apply its innovative gene therapy approach toward a functional cure for HIV.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i><b>&nbsp;</b></i></p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Cautionary Note Regarding Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">This release contains forward-looking statements regarding GeoVax&#8217;s business plans and financial result. This release includes forward-looking statements regarding GeoVax&#8217;s business plan. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;is likely,&#8221; &#8220;will,&#8221; &#8220;expect&#8221; and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax&#8217;s vaccines will be safe for human use, GeoVax&#8217;s vaccines will effectively prevent targeted infections in humans, GeoVax&#8217;s vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax&#8217;s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, the impact of the COVID-19 pandemic continues, and other factors, over which GeoVax has no control.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Further information on our risk factors is contained in our registration statement on Form S-3 that we have filed with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.<b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Contact:</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">GeoVax Labs, Inc.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">investor@geovax.com</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">678-384-7220</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">###</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo01.jpg
<TEXT>
begin 644 logo01.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[@ A061O8F4 9$     ! P 0 P(#!@
M             /_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$!
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\( $0@ -0#' P$1  (1 0,1 ?_$ /$   (# 0$  P$!
M      D*  <(!@4"! L! P$  @,! 0$!            !08 ! <# @@!$
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MZS]-M_(7XKEZL]?BO[W]K/-YB7RS^&C]?>[I7R3Z(_K>N%[][5X%O-TU_]H
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MJ[HQ;O1QM3Y,<K",,;(BZ(NB-D;K)S>1\2PB)P\S#-T3VHF8^5 <6/F+?O\
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MUX_Z7_\ GGQE7_++])>4]S7_ '8]MO=GTAYOVSKT_P";^L?Z5]3^7]3DZ/\
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KG",F8B1; T33N59,C$)P3<YI"1B'=;34(E(A(M8EM3E7IW+%>12;IK?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
